Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBP608 Safety and Immunogenicity in Healthy Adults
NCT03121638Phase 1Completed
- Sponsor
- SK Chemicals
- Start
- Nov 2012
- Primary completion
- Feb 2013
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NBP608 in varicella (VZV) and herpes zoster (HZ) (5 arms), sponsored by SK Chemicals. Primary endpoint: Incidence Rate of Adverse Event at 42 days. Started Nov 2012; status: completed.
02
Drugs
NBP608
03
Conditions
varicella (VZV)herpes zoster (HZ)
Beyond the preview
Go deeper on NCT03121638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121638.